Introduction
In this paper, we attempt to summarize developments ofimportance for practising hospital clinicians and for primary care doctors who must be aware of the ever-widening spectrum of recognized pathogens. This article is restricted to considerations of pathogenic bacteria and antibacterial drugs that have obliged us to change our strategies or policies in the last decade or so. There have been many confusing developments. Whilst basically new antibacterial drugs are rare, variations on previously successful models have been very numerous and some significant progress has been made.
Over the decade, several new infective challenges have posed problems for clinicians and microbiologists. It is recognized that communityacquired infections differ from hospital-acquired infections in the range and nature and antibiotic resistance profiles of the causative organisms. The inexorable progress of bacterial drug resistance has obliged us to reconsider first-choice therapy for some infections.
Beta-lactamase production by various bacteria has restricted our therapeutic options or has obliged us to use new preparations. For example, our recognition of the pathogenic potential of Moraxella (Branhamella) catarrhalis has required modification of previous approaches to the antibiotic therapy of respiratory tract infections, and beta-lactamase-producing strains of Haemophilus influenzae have created further problems. Worrying outbreaks of a range of infections from legionellosis to salmonellosis have extended us to determine or define appropriate therapy. Our evolving awareness of human immunodeficiency virus (HIV) disease and associated opportunistic bacterial infections obliges us to consider a variety of new challenges, especially mycobacterial infections.
Our relative lack of success in dealing with some aggressive infections, such as those caused by the meningococcus or Haemophilus influenzae, has called for a review of our prophylactic strategies, and this has been highlighted in the case of pneumococcal challenges in compromised (asplenic) patients. The common occurrence of polymicrobial or mixed bacterial infections has been acknowledged, and the neglected concept of pathogenic synergy has been revived. The problems of antibiotic-associated diarrhoea have necessitated scrutiny of precipitating antibiotics and studies of the most effective therapy. Meanwhile, the general acceptance of the principle of peroperative antimicrobial prophylaxis and its application to specific areas of operative surgery has had a major impact.
Changes in first-line choices
The sulphonamides have been largely superseded by newer drugs in the last decade, though they are still used, often in conjunction with trimethoprim (as cotrimoxazole), in the treatment of uncomplicated urinary tract infections. Resistance to sulphonamides is common and it is arguable that the use of the combination is now often irrational. Thus, trimethoprim has emerged as a single drug in its own right, but its use too has often been overtaken by the development of resistance. Nalidixic acid has been superseded by the development of the more potent 4-quinolones, and nitrofurantoin is not favoured by many clinicians. Some ofthese drugs have special roles that maintain them in our formularies for the 1990s although they are not now in general daily use. surgeons and others who valued their efficacy against gram-positive cocci and anaerobes and their good penetration into bone. Clindamycin is still highly regarded as an alternative to penicillin when such an option is sought. Unfortunately, the association with pseudomembranous colitis (PMC) has understandably inhibited the general use of clindamycin. It should be noted that the volume of use of ampicillin ensures that ampicillin features prominently in the PMC league table; our experience in the last decade shows that no antibiotic is exempt. Nevertheless, the association with the lincosamides is especially clear and is a justifiable (though not absolute) restraint.
The staphylococcus has sequentially challenged all of the antibacterial drugs as they have been developed and widely used, and has obliged us to keep our therapeutic options open. Thus, fusidic acid (usually in combination with another drug) is still useful. Strains of methicillin resistant Staphylococcus aureus (MRSA) have posed special problems. Vancomycin retains a remarkable place in our attempts to control coagulase-negative staphylococcal infections and MRSA infections (and pseudomembranous colitis caused by Clostridium difficile). It is worrying that our options in these difficult situations are so limited and that we are so dependent on such a restricted number of active agents.
The basic armament
Many antibacterial drugs have stood the test of time, despite our abuse of them over the years. Accordingly, the list of those regarded as first-line choices for the 1990s does not differ significantly from the 1980 list. We now consider developments in antibacterial drug strategy and practice in the last decade in relation to changing aspects of infection. The following account reviews developments in the use of our main-line antibacterial drugs and draws attention to important new applications.
The penicillins
Williams' recognized the following 4 groups of penicillins.
Group I contains benzyl penicillin (penicillin G), the original and still probably the best,2 and analogues such as the orally active phenoxymethyl penicillin (penicillin V).
Group II contains the anti-staphylococcal methicillin and the clinically useful orally active cloxacillin series.
Group III contains penicillins with activity against Gram-negative bacilli (coliform organisms and Haemophilus species etc.), but susceptible to beta-lactamases. These include: (1) ampicillin and amoxycillin (the amino penicillins); (2) carbenicillin and other carboxypenicillin analogues; (3) acyl ureido penicillins such as mezlocillin, azlocillin and piperacillin; and (4) amidino penicillins such as mecillinan. It is most important to note in practice that none of the Group III penicillins is completely stable to the beta-lactamases.
Group IV holds the only true penicillin that is beta-lactamase stable, temocillin, but the activity of this drug does not extend beyond the aerobic Gram-negative bacteria.
Beta-lactamase inhibitors As bacterial resistance to beta-lactam antibiotics is largely attributable to potent bacterial beta-lactamases, pharmaceutical companies sought to develop beta-lactam drugs that are resistant to these enzymes (q.v.). Another strategy is to develop preparations in which a sensitive beta-lactam drug is protected by a betalactamase inhibitor such as clavulanic acid or sulbactam or tazobactam.
These inhibitors have some antibacterial activity in their own right, but their role in the combination is to shield the more active drug. This has extended the usefulness of drugs such as amoxycillin against beta-lactamase-producing staphylococci, coliform organisms and anaerobes including Bacteroides fragilis. However, Pseudomonas aeruginosa has innate resistance to amoxycillin and this still holds.
The combination of amoxycillin with clavulanic acid (co-amoxiclav) is marketed in Britain as Augmentin; ticarcillin with clavulanic acid is Timentin; and ampicillin with sulbactam is sultamicillin.3 Tazobactam in combination with piperacillin is a useful development of this theme. 4 Meanwhile, the pharmaceutical industry was developing the cephalosporins as an alternative answer to the threat of the penicillinases.
The cephalosporins and related drugs
These drugs can be classified into 4 groups that reflect an extending clinical requirement for a range of activity or specific efficacy.' Group I drugs (examples cephaloridine, cephazolin) are highly active against Gram-negative bacteria, notably staphylococci and streptococci.
Group lcephalosporins (examples cefamandole, cefuroxime) are effective against Gram-positive cocci and (Gram-negative) coliform organisms, but not pseudomonas.
Group III drugs (examples cefotaxime, ceftazidime) are active against Pseudomonas and related species, in addition to their activity against enterobacteria. Cefotaxime is less active than ceftazidime against Pseudomonas aeruginosa. Cefsulodin was developed specifically as an antipseudomonal cephalosporin.
Group IV contains the cephamycins (examples cefoxitin, latamoxef, cefotetan) with broadspectrum efficacy that includes activity against anaerobic bacilli such as bacteroides organisms, the clostridia, and anaerobic cocci.
As in the case of the penicillins, it should be noted that evolving bacterial resistance may limit the usefulness of the drugs in each of these groups.
Monobactams
Aztreonam is a monocyclic beta-lactam with remarkably narrow-spectrum activity against aerobic Gram-negative bacteria, notably the enterobacteria, the gonococcus and Haemophilus influenzae.6 Carbapenems Imipenem has a remarkably broad spectrum of activity against the enterobacteria, and Pseudomonas aeruginosa, Haemophilus influenzae, Bacteroides spp., staphylococci and streptococci.7 Imipenem has to be given with cilastatin to inhibit the action of renal dehydropeptidase which inactivates the drug. Meropenem has equivalent activity and is resistant to the action of the renal enzyme. 8 For comparative data on the beta-lactam antibiotics, the reader is referred to Rolinson's informed paper.9 An account of the mechanisms and clinical significance of resistance to new betalactam antibiotics is given by Livermore and Wood.'1 Aminoglycosides These drugs are not absorbed after ingestion and are normally injected, unless a local effect on an intestinal pathogen or on the gut flora is desired. In the latter case, aminoglycosides are still used irrationally because they are not effective against anaerobic bacteria or streptococci, though they have a synergistic effect with penicillin when used in combination parenterally against streptococci.
Streptomycin now has only a limited place in the management of tuberculous infections, and it has been largely replaced in the therapy ofother serious infections by more recent members of the series such as gentamicin, tobramycin, netilmicin, and amikacin." With the exception of amikacin, these later developments are not adequately effective against the tubercle bacillus. They all have prompt and highly useful activity against coliform bacteria including pseudomonas, though resistance is a recurring problem if they are not used carefully. It should be remembered that therapy with aminoglycosides may suppress the growth of mycobacteria in specimens submitted for culture to exclude a diagnosis of tuberculosis. This is import- Although the toxicity of the aminoglycosides for the middle ear and the kidney limits their use and obliges the clinician to monitor peak and trough levels during therapy, these drugs are still favoured by many clinicians for the therapy of serious infections. They are often used in combination with a pencillin and sometimes with metronidazole to extend the spectrum until the nature of the infection is known. This is an area of current debate, as others prefer to base therapy in such circumstances on one of the broad-spectrum cephalosporins or related drugs such as ceftazidime and to add in other drugs as necessary. '6 Spectinomycin has special usefulness in the treatment of gonococcal infections (1) in patients who are allergic to penicillin, or (2) in cases of infection with penicillinase-producing strains. '7 Tetracyclines These drugs were active across a remarkably wide spectrum, but bacterial resistance and recognized adverse effects limit their use. '8 The adverse effects of the tetracyclines are mainly related to the gastro-intestinal tract and superinfection, and to the sequestering of the drug in bone and teeth so that they are not given as a routine during pregnancy or childhood. It was later found that the anti-anabolic effect of tetracyclines may precipitate or exacerbate renal failure in patients with impaired renal function. Table I ). Their comparative in vitro properties were reviewed in 1988 by Hardy et al. 3" In general, the activity of the 14-membered macrolides equals or exceeds that of erythromycin, whereas the 1 5-membered azithromycin is less active against Gram-positive but more active against Gram-negative bacteria. The 1 6-membered macrolides are less active than erythromycin. Clarithromycin is the most active compound against Steptococcus pyogenes, pneumococci, Listeria monocytogenes and Corynebacterium spp., and it shows promising activity against Mycobacterium avium. Miocamycin, clarithromycin and rokitamycin are the most active compounds against L. pneomophila. Azithromycin is the most active compound against Moraxella catarrhalis, Neisseria gonorrhoeae, and Haemophilus influenzae.
Bernstein, Roudier and Fleurette32 tested several macrolides against Legionella spp. on charcoal-free media to avoid inactivation of antibiotics by charcoal and found that the most active agents were josamycin (0.06-0,25 mg/1), pristinamycin (0.06-0.5 mg/l) and erythromycin (0.12-0.5 mg/l).
Clarithromycin is an acid-stable 14-membered macrolide that achieves higher serum levels than erythromycin and has twice the serum half-life.33 In general, the MIC's for common respiratory pathogens are 2-4-fold less than those of eryth- 
Fusidic acid
This steroid-like compound has clinically useful activity against staphylococci. As any large population of staphylococci is likely to contain mutants resistant to fusidic acid, the drug is usually given along with a penicillin or some other antibiotic to suppress their emergence during therapy.34
Rifamycins Rifampicin, the original member of this class to be used therapeutically, has for many years been the cornerstone of multi-drug regimens for the treatment of tuberculosis. More recently, it has been used for the prophylaxis of meningococcal infection and treatment of carriers (but see later in this paper), and for the treatment of severe legionella infection in combination with erythromycin. It is also of use for the prophylaxis of Haemophilus influenzae meningitis among those exposed to this infection (see Fleming) .3"
The increasing problem of mycobacterial infections in acquired immunodeficiency syndrome (AIDS) patients, often with rifampicin-resistant species such as Mycobacterium avium, led to a search for more active rifamycin derivatives. Dickinson and Mitchison36 reported that rifabutin and rifapentine showed good in vitro activity against strains of the M. avium complex. Other workers have shown rifabutin to be more active in vitro than rifampicin, especially against M. avium strains3738 and to show synergy with ethambutol against some of them.39 However Metronidazole is potentially irritant on intravenous injection and may cause phlebitis. Neuropathy has been reported as a possible untoward effect after prolonged high dosage. Nausea and mild gastrointestinal upsets have been noted as side effects, and skin rashes and leucopenia are listed as rare adverse reactions. Patients must be warned to avoid alcohol when taking nitro-imidazole drugs.
Quinolones
These synthetic compounds are derived from nalidixic acid which has been used as a urinary antimicrobial agent for many years. Nalidixic acid is given orally and achieves good levels in the urine but low serum levels, so that its use is limited to the prophylaxis and treatment of urinary tract infec- New challenges and changes in concept and practice
Limitations of space oblige us to be selective in this review of our changing use of antibiotics.
Dosage strategy
Our standard teaching on the antibiotic management of an acute infection has been to give a full course of an effective antimicrobial drug at an appropriate dosage. In some cases, there is a trend away from this dogma. For example, it is standard practice now to give a short sharp course of a suitable drug to treat an acute primary urinary infection. In general, however, the principle of 'strong enough for long enough' still holds. The dosage and duration oftherapy has been advocated in some detail for special cases and circumstances. One of the disadvantages of the clinician's awareness of the potential toxicity of drugs is that some antibiotics are given in sub-optimal dosage. This merits special attention with aminoglycoside therapy in which peak and trough levels must be monitored to ensure not only that toxic overdosage is avoided but that underdosage does not occur."
Prophylaxis and suppression ofinfection
We have become more permissive in our approaches to the borderland of prophylaxis, suppression and treatment of infection. The antibacterial protection of patients at risk from bacterial endocarditis while undergoing dental treatment or other clinical procedures is very well established, with clear guidelines. 
Atypicalpneumonia
The term atypical pneumonia (originally a radiological description) is now usually used to describe pulmonary consolidation of uncertain aetiology, or from which 'conventional' bacteriological cultures have failed to reveal an obvious pathogen. In recent years the main causes of atypical pneumonia have been mycoplasmas, legionellae, chlamydiae and Coxiella burnetii.
Mycoplasmas can cause a variety of human infections but only M. pneumoniae causeg respiratory infection. Respiratory infection with this organism is world-wide in distribution, occurring in late summer and autumn. It is thought that in the USA M. pneumoniae infects about 6% of the population annually.65 Epidemic peaks are well recognized. In general, the organism causes mild respiratory-tract symptoms but more serious infections can occur, especially in children, with patchy consolidation that is sometimes bilateral. Symptoms and X-ray changes may persist for several weeks, with frequent relapses. Although the infection is rarely fatal, respiratory impairment may persist for some months, especially in adults.
Legionnaire's disease, first described in 1976,' is 67 in the Nottingham area indicated that the organism was responsible for up to 15% ofcases of pneumonia, but a repeat study68 suggested that the figure then was nearer 5%.
The best recognized chlamydial infection is psittacosis, caused by C. psittacii. Although classically associated with parrots, the infection may be acquired from a wide variety of species ofbirds that have included ducks and fulmar petrels. It is now accepted that most species of birds can excrete the organisms.69 Infection is acquired by the respiratory route and some strains are highly infectious so that brief contact with an infected bird may be sufficient to ensure infection. Person-to-person spread, although described, is rare. Psittacosis may present abruptly with fevers, rigors and headache. Although there are few respiratory signs or symptoms, there is often radiological evidence of extensive pneumonitis. In severe cases, the infection may involve the liver, central nervous system and myocardium, with an appreciable mortality rate.
In recent years, another species of chlamydia, C. pneumoniae70 has been recognized as a cause of respiratory tract infection, usually presenting as bronchitis or pneumonia with similar clinical features to those caused by M. pneumoniae. Q fever, caused by Coxiella burnetii is a potentially serious infection that can affect many different systems, including the respiratory tract. Although many cases are self-limiting, in serious cases the disease may affect a wide variety of systems including the lungs, with up to 50% having radiological signs of pneumonia. Chronic infection is well recognized as a cause of 'culture-negative' endocarditis. The infection is spread by inhalation of aerosols from infected sheep, goats or cattle, or by ingestion of infected unpasteurized milk. Person-to-person spread is rare but laboratoryacquired infection is well recognized in workers handling infected material. Treatment The atypical pneumonias do not respond to the normal antibiotics given for respiratory tract infections (usually beta-lactams). Q fever responds to tetracyclines, notably oxytetracycline; rifampicin and trimethoprim may be useful alternatives.7' Erythromycin is effective, as are the tetracyclines, against mycoplasmas and chlamydial infections, while erythromycin is an effective drug against legionellae, supplemented by rifampicin in severe cases. The fluoroquinolones showed promise of efficacy against mycoplasmas and legionellae but their activity has not so far been confirmed in clinical trials.
Gastro-intestinal and intestinal infections
These continue to include the well-known classics of bacillary dysentery, salmonella food poisoning and an extending range of food-borne intoxications and infections, typhoid fever and related enteric fevers, and giardiasis. The clinician has had to contend with a widening spectrum from rotavirus infections, all of the variations of enteropathogenic Escherichia coli, yersiniosis and listeriosis, to campylobacter gastroenteritis and colitis, antibiotic-associated diarrhoea and pseudomembranous colitis, and the now established role of Helicobacter pylori in relation to peptic ulcer.
When this review was written in 1991, antibiotics had a limited role in the clinical management of intestinal infections but some useful applications are recognized.
Metronidazole has earned its place in the therapy of entamoeba infections and giardiasis. Erythromycin can help in the management of campylobacter gastro-enteritis or colitis, but the indications for its use are not yet clearly drawn; parenteral gentamicin may be used for severe septicaemic cases. Vancomycin is established as the preferred agent for therapy of pseudomembranous colitis, while metronidazole is generally regarded as a second option.
Chloramphenicol seems to retain its place as the first choice for the treatment of the enteric fevers (typhoid and paratyphoid), though some typhoid bacilli are resistant and other factors merit consideration. 24 The specific antimicrobial treatment of acute purulent meningitis varies with the causative organism, if it is known. Clinicians in the UK recognize that the league leaders are the meningococcus and Haemophilus influenzae and that the age of the patient must be considered in assessing the possible infective agent. Thus, neonatal meningitis is likely to be caused by Escherichia coli or a Group B streptococcus.
It is important to check the sensitivity of the strain involved. As resistance to ampicillin is not uncommon in H. influenzae, chloramphenicol has a special role here. We watch with concern the occurrence of chloramphenicol resistance in haemophilus bacteria in some countries. Penicillin or chloramphenicol are generally used for the treatment of meningococcal meningitis. Penicillin is the drug of choice for the treatment of pneumococcal meningitis. Penicillin-resistant pneumococci are well known to occur in some parts of the world. Even when the strain is fully sensitive to penicillin, it is acknowledged that the results of treatment of pneumococcal meningitis may be disappointing.
The initial blind therapy for a patient with acute purulent meningitis takes account of the likely causes and may include chloramphenicol and penicillin. Some clinicians now favour the use of cefotaxime or ceftriaxone. The subject is very well reviewed by Ispahani.84 Prophylaxis ofcontacts ofacute bacterial meningitis Until the development of sulphonamide resistance in meningococci, the prophylaxis of close contacts of a case of meningococcal meningitis was straightforward. As penicillin does not eliminate meningococci from the nasopharynx, a short course of rifampicin or minocycline was chosen to deal with the carrier state. Minocycline has some disadvantages and rifampicin became established in the preventive role. 85 There are good reasons to regard ciprofloxacin as a preferred alternative, because rifampicin has so many other important uses and should be protected. However, the people to be protected often include young children and there is some reluctance to give ciprofloxacin to young children. The giving of a short course may well be justified, but there is no authoritative pronouncement to date.
Meanwhile, the concept of prophylaxis has changed. An important difference has been recognized between the early colonization that represents an incipient infection ('co-primary infection') and the established carrier state.86 In the former situation, a course of penicillin would abort the attack as it is being mounted. This action would be reasonable for the immediate protection of the close contacts of a case of meningococcal meningitis and it is now established practice in Norway. In Britain, rifampicin is still the standard prophylactic in this context and (at different dosage) we are beginning to follow accepted US practice in regarding rifampicin as the recommended antibiotic for the protection of close contacts of Haemophilus influenzae meningitis.87
Chlamydial infections
Chlamydiae cause infections of the eye, the genital tract and adnexa, and the respiratory tract. As these organisms also cause infections in animals, there may be an occupational link in some cases (e.g. farmers, veterinary workers, abattoir workers, owners of pets). Laboratory diagnosis has improved in recent years. Therapeutic options have widened to include erythromycin, tetracyclines, and the quinolones -although the early promise of the latter has still to be realized. Newer quinolone derivatives may give better results, but erythromycin is the first-line choice and the tetracyclines are close alternatives.
Pelvic inflammatory disease occurs in women as a result ofan ascending infection in the genital tract with endometritis, salpingitis and salpingo-oophoritis. There is a strong association with sexual intercourse and it is thought that spermatozoa may act as carriers that allow non-motile potential pathogens to gain access to the upper genital tract. A mixed infection often occurs in which gonococci or chlamydiae (or both) may be present with aerobic or anaerobic organisms. The anaerobic component often includes bacteroides organisms. Accordingly, treatment with a single antibiotic is unlikely to be effective. Careful investigation and combination therapy are essential.
This subject was authoritatively reviewed by Pearce88 who considered that treatment with parenteral antibiotics should include a single dose of ampicillin and probenecid to control gonorrhoea; a I -week course ofgentamicin or a second generation cephalosporin to deal with coliform opportunists; a 2-week course of metronidazole to eradicate anaerobes; and a 2-week follow-up course of doxycycline or erythromycin to eradicate chlamydiae. We sympathize with the patient confronted with such a regimen, but we have to call attention to the many failures and all of the morbidity that have attended less thorough approaches to the therapy of this distressing condition.
Compromised hosts
The term is now used too loosely and our experience of opportunistic infections in the last 10 years teaches us to be more specific and more discriminating. It may be said that any infective pathogen is opportunistic, taking advantage of circumstances and special sets of variables in the host-parasite relationship to express aggression and virulence. It is increasingly recognized that certain forms of compromise are associated with known ranges of potential infections. Thus, for example, foreign bodies and prostheses inserted into tissues may act as foci for infection with Gram-positive cocci, diphtheroid organisms or yeasts, whereas neutropenic patients are at special risk of generalized infections with coliform organisms or cocci (see below).
Patients who have inadequate spleens (hyposplenism) or who have lost their spleens as a result of operative removal after injury or for therapeutic reasons, are vulnerable to overwhelming infection with pneumococci and some other pathogens that include Pseudomonas aeruginosa and Capnocytophaga canimorsus.89 As functional hyposplenism is known to occur in sickle-cell anaemia, coeliac disease and bone-marrow transplant recipients, clinicians must be vigilant.
The reader is referred to a succinct reminder of the range of patients who may be chronically immunodeficient as a result of diseases ranging from diabetes mellitus to AIDS. 90 The prevention of pneumococcal infections in those at special risk rests primarily upon awareness of the individual's susceptibility which must be clearly recorded. Pneumococcal vaccine affords some protection, but not for young children aged less than 2 years. As the protection afforded lasts for about 5 The principle of a selective parenteral and enteral antisepsis regimen (SPEAR)97 is an extension of the concept of selective decontamination of the gut (q.v.) to prevent superinfection in severely injured patients.9800 Promising claims are being made and this approach merits further study and cautious application, with special attention to the drug resistance profiles of the bacterial pathogens encountered.
Antibiotic-associated diarrhoea and pseudomembranous colitis
Adverse reactions to antibiotics include gastrointestinal upsets and diarrhoea. Antibiotic-associated diarrhoea is quite common and is usually self-limiting, stopping when the course ofantibiotic is completed. In some cases, severe diarrhoea necessitates premature withdrawal of the provoking antibiotic. It has become increasingly recognized that some antibiotics are more likely than others to upset the normal bowel flora and to render the bowel more vulnerable to invasion and overgrowth by potential pathogens. The concept of the colonization resistance ofthe normal bowel as a function of its normal flora was advanced by Van der Waaij and colleagues.'0' These workers advocate the classification of antibiotics into 3 groups: (1) those that markedly alter the bowel flora and suppress colonization resistance, such as ampicillin and some other penicillin derivatives; (2) those that are intermediate in this context, such as the aminoglycosides and some parenteral cephalosporins; and (3) those that are 'indifferent' and exert no effect on colonization resistance, such as cephradine and cotrimoxazole.
Loss of colonization resistance and overgrowth with other organisms is worrying, because potential pathogens may be enriched and resistance transfer may be encouraged within and between the new populations of organisms. Clostridium difficile is one of special concern. If this organism is enriched in the bowel, it produces a range of toxins and gives rise to pseudomembranous colitis which is potentially fatal.'02 If C. difficile or its cytopathic toxin is identified in the stools of a patient with The present epidemic of HIV infection has been associated with an increase in mycobacterial infections and the observed increase in notifications both in England and Wales and in Scotland in 1989 and 1990 may be due to this but it is likely that other factors are also responsible. Infection with M. tuberculosis is a feature ofthe relatively early stages of HIV infection and, although tuberculosis may present abnormally in these patients (as a generalized infection with fairly non-specific lung signs) it is amenable to treatment with standard therapy. In the later stages of the disease when the patient has developed AIDS, infections with other mycobacteria, notably Mycobacterium avium, are a feature. These infections are often difficult to treat and may prove to be terminal events. It is difficult to know whether such an infection is merely a marker of a very severely depleted immune system or whether it precipitates further deterioration in immunity. There are no recognized protocols for treating these infections and individual clinicians use different drug combinations that often include amikacin, rifampicin (or rifabutin). Much work needs to be done to establish the best treatment for these mycobacterial infections.
Many of the 4-quinolones possess antimycobacterial activity. Some of the more recent ones still under development, for example, sparfloxacin, show considerable promise.56 To date there have been no formal clinical trials, but studies are to commence in some European countries in the near future. Quinolone compounds may well prove to be a useful addition to the therapeutic armamentarium of anti-mycobacterial drugs.
Bacterial drug resistance
This problem is unrelenting. In the last decade, we have seen penicillin resistance extending into a wide range of organisms that include Haemophilus influenzae and Neisseria gonorrhoeae. ' It has been known for years that genetic information endowing bacteria with antibiotic resistance can be transferred by various mechanisms that include transduction by phage, and by conjugation which has some parallels with sexual forms of transmission. The transfer of plasmids between related bacteria allows packets ofresistance information to be exchanged, and the potential harm of plasmidmediated resistance is well recognized. There are now examples of exchanges of resistance information between coliform bacteria that cross taxonomic boundaries and qualify for the description of promiscuous behaviour. These interlinked systems account for the daunting speed of the transmission of bacterial drug resistance information so that resistant strains are encountered rapidly across the world."0 This has been assisted by transposons which are small bits of DNA that are able to jump between plasmids in the same cell."' To add further to the complexity of the scenario, it is now becoming clear that a mechanism of genetic exchange resembling transformation may account for the exchange of plasmid-borne information in coliform bacteria, while conjugation systems may operate in Gram-positive bacteria that we previously thought were unable to exchange DNA in this way.
We have had to extend our understanding of the range of pathogens that readily acquire resistance."2 In recent years we have recognized that Moraxella (Branhamella) catarrhalis is not merely a respiratory commensal but can be an important respiratory tract pathogen."3 M. catarrhalis is resistant to some of the antibiotics commonly used for the treatment of respiratory tract infection, especially ampicillin/amoxycillin, due to beta-lactamase production. Over 70% ofclinical isolates are beta-lactamase producing, in our experience at the City Hospital Bacteriology Laboratory, Edinburgh.
Another pathogen that may be resistant to penicillins because of beta-lactamase production is Haemophilus influenzae. A recent revieweri5 indicated that 10% of non-capsulate and 25% of type b strains from blood and CSF in the UK were beta-lactamase positive. Some non-capsulate strains resistant to ampicillin (MIC > 1 mg/l) are betalactamase negative, the mechanism of resistance being chromosomal in nature. Such strains are often resistant to several beta-lactams. The first reports of resistance to methicillin in staphylococci appeared soon after the introduction of the drug in 1959. Although sporadic outbreaks ofinfection due to these organisms occurred, it was not until the 1980s that they posed significant problems in the UK and elsewhere"8 in relation to hospital infection control.
Some strains are more transmissible than others ('epidemic methicillin-resistant Staph. aureus' EMRSA)."19 Such strains often belong to a single phage group although many are untypable by standard phages. Most MRSA strains have a special ability to colonize skin and anterior nares and to spread from person to person, though they are not more virulent than methicillin-sensitive strains. The problems that they pose relate to control of spread of infection and to treatment of established infections, when methicillin and flucloxacillin are inactive.
Spread of infection has to be controlled or prevented by rigorous control of infection measures such as those laid down by the Joint Working Party of the Hospital Infection Society and British Society for Antimicrobial Chemotherapy. '20 In addition, the development of mupirocin (a pseudomonic acid) as a topical specific anti-staphylococcal agent has enabled efforts to be made to eradicate nasal and skin carriage by applying mupirocin ointment and group.bmj.com on June 19, 2017 -Published by http://pmj.bmj.com/ Downloaded from mupirocin in a polyethylene glycol base respectively.
Treatment of established infections may be difficult, as strains of MRSA are usually resistant to gentamicin and chloramphenicol as well as to methicillin and flucloxacillin. Many authorities suggest vancomycin, alone or in combination with rifampicin."8-'20 Newer agents such as teicoplanin a glycopeptide antibiotic with similar activity to vancomycin) and ciprofloxacin offer promise'2' though strains of MRSA that are resistant to ciprofloxacin have been described and therapeutic failures reported. It has become clear that the presence of an implanted prosthesis or venous line may provide a nidus for continuing infection and that removal of the device may be necessary to eradicate the infection.
